Advances in Bowel Preparation for Colonoscopy




Precolonoscopy bowel preparation is adequate to identify lesions larger than 5 mm about 70% to 75% of the time, but the opportunity for further improvement exists. The use of high-quality formulations with established efficacy rates of 90% or greater, identification of patients who are at increased risk of an inadequate preparation, as well as patient education and motivation to be invested in the process further improves the success of cleansing. Endoscopists should strive to achieve an adequate bowel preparation in 85% or more of patients. High-quality colonoscopy requires high-quality bowel cleansing.


Key points








  • Selection of a bowel preparation agent should be tailored to the needs of each patient with particular attention to individuals with chronic constipation, multiple comorbid conditions, or an inadequate preparation during prior colonoscopy.



  • Patient education and willingness to participate in the preparation process can improve the outcome of bowel cleansing.



  • Endoscopists should be prepared to spend time during each procedure cleaning the colon. The quality of bowel preparation should be assessed during scope withdrawal when cleaning efforts have been completed.



  • An adequate preparation permits the detection of lesions greater than 5 mm in size and is defined as one that enables the examiner to adhere to current guidelines for colorectal cancer screening and surveillance.



  • Practitioners should benchmark the proportion of their colonoscopies with an adequate preparation and should aim to meet or exceed a threshold rate of 85%.






Introduction


Despite its straightforward purpose and unpretentious name, bowel cleansing for colonoscopy remains a challenge for endoscopists and patients alike. Its objective to remove all solid and liquid debris from the colon lumen in order to make it possible for the operator to perform a thorough examination of the mucosal surface seems simple enough. Nonetheless, roughly 1 in 4 colonoscopies performed in the United States and western Europe are considered to have an inadequate-quality preparation. Even a thin film of mucus or chyme coating the mucosa may obscure a clinically important lesion. The introduction of split-dose regimens has significantly enhanced the ability to achieve high-quality cleansing, especially within the proximal colon, and has improved the detection rate of flat polyps that may be readily obscured by mucosal staining or a small pool of fluid.


Coincident with efforts to design a more effective dosing schema have been attempts to develop effective purgatives that are more acceptable to patients. Several lower-volume preparations have recently been approved in the United States. Notwithstanding these efforts, conventional 4-L polyethylene glycol (PEG) with electrolytes remains the benchmark by which the efficacy of other preparations should be compared.


In an effort to improve the overall quality of bowel preparation, and consequently the quality and effectiveness of colonoscopy, the US Multi-Society Task Force (MSTF) on colorectal cancer (CRC) now recommends that clinicians meet or exceed a target rate of 85% for adequate bowel preparation. While acknowledging that rates of adequate preparation are related, in part, to a variety of patient factors such as age, gender, comorbid disease, and socioeconomic status, and that differences in these and other variables from practice to practice can significantly affect the proportion of patients with an adequate preparation, the gastrointestinal professional societies think that it is possible for most practitioners in the United States to achieve this goal. However, for some endoscopists it will require a reformulation of their approach to bowel preparation with greater emphasis on patient education, increased patient activation, adoption of preparation agents that have track records for high rates of success, and the implementation of split-dose regimens. This article reviews recent updates to bowel preparation guidelines and the evidence supporting these recommendations.




Introduction


Despite its straightforward purpose and unpretentious name, bowel cleansing for colonoscopy remains a challenge for endoscopists and patients alike. Its objective to remove all solid and liquid debris from the colon lumen in order to make it possible for the operator to perform a thorough examination of the mucosal surface seems simple enough. Nonetheless, roughly 1 in 4 colonoscopies performed in the United States and western Europe are considered to have an inadequate-quality preparation. Even a thin film of mucus or chyme coating the mucosa may obscure a clinically important lesion. The introduction of split-dose regimens has significantly enhanced the ability to achieve high-quality cleansing, especially within the proximal colon, and has improved the detection rate of flat polyps that may be readily obscured by mucosal staining or a small pool of fluid.


Coincident with efforts to design a more effective dosing schema have been attempts to develop effective purgatives that are more acceptable to patients. Several lower-volume preparations have recently been approved in the United States. Notwithstanding these efforts, conventional 4-L polyethylene glycol (PEG) with electrolytes remains the benchmark by which the efficacy of other preparations should be compared.


In an effort to improve the overall quality of bowel preparation, and consequently the quality and effectiveness of colonoscopy, the US Multi-Society Task Force (MSTF) on colorectal cancer (CRC) now recommends that clinicians meet or exceed a target rate of 85% for adequate bowel preparation. While acknowledging that rates of adequate preparation are related, in part, to a variety of patient factors such as age, gender, comorbid disease, and socioeconomic status, and that differences in these and other variables from practice to practice can significantly affect the proportion of patients with an adequate preparation, the gastrointestinal professional societies think that it is possible for most practitioners in the United States to achieve this goal. However, for some endoscopists it will require a reformulation of their approach to bowel preparation with greater emphasis on patient education, increased patient activation, adoption of preparation agents that have track records for high rates of success, and the implementation of split-dose regimens. This article reviews recent updates to bowel preparation guidelines and the evidence supporting these recommendations.




Bowel preparation and its impact on colonoscopy quality


The quality of bowel cleansing at colonoscopy should be assessed during scope withdrawal, after all efforts at washing and suctioning fluid and debris from the lumen have been completed. Such an approach to grading largely discounts the presence of retained fluid and small bits of stool, because these can usually be removed during the procedure. Given its importance in improving the quality of colonoscopy, the time required for adequate washing should not be minimized. A recent prospective study found that the mean time spent washing/suctioning during colonoscopy was 4.1 minutes. As anticipated, the time and the volume of instilled fluid were inversely proportional to the baseline preparation grade, ranging from 2.7 to 9.2 minutes and 167 to 807 mL for excellent to poor preparations, respectively. In 33 (6%) patients, the quality of preparation was substantially improved, from fair/poor to good/excellent (or inadequate to adequate). This finding shows that intraprocedural washing and cleaning are integral components of the examination and can have an appreciable impact on the quality and cost-effectiveness of colonoscopy. The time allotted for each procedure should therefore be sufficient for the endoscopist to thoroughly cleanse those segments of the bowel that are not adequately prepared during the preprocedure period.


The quality of the bowel preparation should be recorded in a written report generated after each colonoscopy. Many clinicians use a nonstandardized 4-point scale (excellent, good, fair, and poor) to describe the quality of bowel cleansing, often without a precise definition of each grade. As a result, a preparation rated good by one endoscopist may be considered fair by another. Further, the adequacy of a fair preparation, in terms of adenoma detection, has yet to be fully defined. Nonetheless, many endoscopists shorten the interval between examinations when the quality of the bowel preparation is considered inadequate. For example, a retrospective review of more than 16,000 colonoscopies performed at an academic medical center found that nearly 60% of average-risk patients with normal colonoscopy results underwent early repeat examination because of a preparation quality rated as fair. A recent systematic review and meta-analysis of 11 studies observed no difference in adenoma detection rate (ADR) between examinations with intermediate-quality (fair) compared with those with high-quality preparation (good or excellent) (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.80, 1.10). In contrast, ADRs were significantly higher with both intermediate-quality (OR, 1.39; 95% CI, 1.08, 1.79) and high-quality preparations (OR, 1.41; 95% CI, 1.21, 1.64) compared with low-quality (poor) preparations. Similar findings were observed in an analysis of 13,000 colonoscopies within a statewide registry, with comparable ADRs in examinations with fair-quality versus optimal-quality preparation. If confirmed by other investigators, these findings indicate that a fair-quality preparation could be sufficient for the detection of adenomas during screening and surveillance colonoscopy.


The current emphasis is on classifying a bowel preparation as either adequate or inadequate. An adequate preparation is one that allows the detection of lesions greater than 5 mm in size. As such, the term adequate implies that bowel cleansing is sufficiently good for the examiner to identify clinically important lesions. The US MSTF guidelines define an adequate preparation as one that enables the endoscopist to follow the recommended screening and surveillance guidelines.




Implications of an inadequate bowel preparation


Adenoma detection is currently the most important measure of colonoscopy quality ( Box 1 ). Data from a national endoscopic database indicated that an adequate-quality preparation resulted in a higher detection rate for adenomas of all sizes (OR, 1.21; 95% CI, 1.16, 1.25) compared with an inadequate preparation. Similar findings were observed in a prospective, multicenter European trial in which all polyps (OR, 1.46; 95% CI, 1.11, 1.93) as well as larger (>10 mm) polyps (OR, 1.72; 95% CI, 1.11, 2.67) were detected more often with a high-quality compared with a low-quality preparation. Flat lesions within the proximal colon are also more likely to be detected when the preparation quality is rated as good. For example, a single-center study reported significantly more flat polyps detected with a higher-quality (same-day) versus a lower-quality (day-before) preparation (21.6% vs 9%; P = .02).



Box 1





  • Lower detection rate of adenomas (all sizes)



  • Lower detection rate of flat lesions (proximal colon)



  • Prolonged cecal intubation time



  • Lower cecal intubation rate



  • Increased time washing and suctioning debris



  • Prolonged withdrawal time



  • Increased costs of CRC prevention



  • Patient dropout of CRC prevention program



Adverse consequences of inadequate bowel preparation for colonoscopy


In contrast, poor-quality bowel preparation leads to lower detection rates, which means more missed lesions. Two single-center studies from academic medical centers examined the rate of missed lesions with an inadequate bowel preparation on the index examination, based on the results of a follow-up procedure performed within 3 years of the baseline study. The overall adenoma miss rates were, respectively, 42% and 47.9%. Although the absolute numbers may differ from one center to another, these rates show that significant numbers of polyps, both large and small, are missed with an inadequate preparation.


Operational efficiency is also affected by the quality of bowel preparation. European investigators observed that cecal intubation time (11.9 vs 16.1 minutes; P <.001), instrument withdrawal time (9.8 vs 11.3 minutes; P <.001), and cecal intubation rates (90.4% vs 71.1%; OR, 3.33; 95% CI, 2.36, 4.70) were all better with high-quality than low-quality preparations. As indicated earlier, the intraprocedural time washing the bowel was prolonged with poor-quality preparations.


Endoscopists have long struggled to find the most appropriate follow-up strategy when the quality of bowel preparation is suboptimal. There is evidence of surveillance overuse in low-risk patients and well as underuse in high-risk patients. For example, a review of practice patterns among 152 physicians from 55 practices indicated that more aggressive surveillance strategies were recommended when the preparation quality was good/fair/poor compared with those rated excellent. In an effort to provide better guidance to clinicians, the 2012 MSTF guidelines state that, “If the bowel preparation is poor, the MSTF recommends that in most cases the examination should be repeated within 1 year. … If the bowel preparation is fair but adequate (to detect lesions >5 mm) and if small (<10 mm) tubular adenomas are detected, follow-up at 5 years should be considered.” In order to improve compliance with clinical practice guidelines, both governmental and commercial payers are developing quality measures for colonoscopy that reflect clinicians’ adherence with screening and surveillance guidelines. For example, the Physician Quality Reporting System, developed by Medicare, will begin using payment adjustments in 2015 to encourage physicians to report on specific measures related to follow-up intervals for screening and surveillance examinations. The message is clear: consistent high-quality bowel cleaning is a necessary element of effective and efficient colonoscopy. A rate of 85% has been proposed by the MSTF on CRC as a benchmark for adequate preparation on a per-physician basis.




Difficult-to-prepare patients


Several patient-related characteristics, including age, gender, body mass index (BMI), and hospital inpatient status, have been associated with the quality of preparation ( Box 2 ). The association with higher age and male gender has a low predictability level and is not consistently observed across all studies. In contrast, a large study of 1588 patients found that BMI greater than 25 was an independent predictor of inadequate preparation, with each unit increase in BMI more than 25 increasing the likelihood of inadequate preparation by 2.1%. Further, additional independent predictors of inadequate preparation, combined with high BMI, exponentially increased the risk of a suboptimal preparation.



Box 2





  • Patient characteristics



  • Older age



  • Male gender



  • Higher body mass index



  • Inpatient status




  • Health conditions/medication usage



  • Multiple comorbid conditions



  • Neurologic conditions (stroke, Parkinson)



  • Impaired mobility



  • Prior gastrointestinal surgical resection



  • Diabetes mellitus



  • Spinal cord injury



  • Medications associated with constipation as side effect




  • Social/behavioral characteristics



  • Reduced health literacy



  • Lower patient activation



Risk factors for inadequate preparation


Various medical conditions and medications are also associated with an increased likelihood of inadequate preparation. The list of conditions includes stroke and Parkinson disease, impaired mobility, diabetes mellitus, spinal cord injury, and prior gastrointestinal resection. The medications that have been implicated include narcotics and tricyclic antidepressants. Although the OR for any of these conditions alone adversely affecting the preparation is low, ranging from 1.1 to 3.2, a cumulative effect has been observed so that elderly patients with multiple comorbid diseases have a significantly increased likelihood of having an inadequate preparation. Several investigators have attempted to develop a predictive model using a composite score to increase the success in identifying individuals at risk. One such model had only modest ability to predict an inadequate preparation (area under the curve, 0.63), and its utility in clinical practice seems limited at present.


Additional predictors of inadequate preparation include health literacy and patient activation. Although other variables, such as health insurance status, socioeconomic status, and educational level, have also been observed to predict suboptimal bowel preparation in earlier studies, it is likely that the common denominator is reduced health literacy, which can lead to difficulty or inability to read the educational materials and instructions provided before colonoscopy, failure to comprehend the importance of bowel preparation in the overall success of colonoscopy, or lack of understanding regarding preventive health measures. Patient activation refers to the motivation or mind-set of a patient to participate, or be engaged, in their health care. Although seemingly interrelated, health literacy and patient activation are independent variables as predictors of inadequate preparation. In a recent study of nearly 500 outpatients followed either at an academic medical center clinic or a federally qualified health center, low levels of patient activation (OR, 2.12; 1.3–3.45), but not health literacy (OR, 0.76; 0.38–1.52), was an independent predictor of inadequate preparation. The solution to this problem, put succinctly in a recent editorial, is “education, motivation, and reminders.” This can be in the form of 1:1 teaching sessions, bowel preparation classes, instructional videos, online tutorials, or in some cases patient navigators. More research is needed to develop better methods for improving patient understanding and willingness to become actively involved in the preparation process.




Selecting a bowel preparation agent


Prescription Agents


Bowel cleaning agents for precolonoscopy preparation have evolved from large-volume (7–12 L) solutions with hypertonic saline to osmotically balanced solutions containing PEG and electrolytes. Originally formulated as a 4-L preparation, a lower-volume PEG regimen combined with an adjunctive agent (MoviPrep, Salix Pharmaceutical, Raleigh, NC) was subsequently developed in order to improve patient tolerance. Sodium phosphate solution, another popular preparation that was available for almost 20 years, was withdrawn from the US market in December 2008 because of concern over phosphate-induced renal insufficiency. However, a tablet formulation of sodium phosphate (OsmoPrep; Salix Pharmaceuticals, Raleigh, NC) remains available by physician prescription. In addition, oral sodium sulfate (SUPREP, Braintree Laboratories, Braintree, MA), sodium picosulfate/magnesium citrate (Prepopik, Ferring Pharmaceuticals, Inc, Parsippany, NJ), and a combination preparation that includes PEG plus sodium sulfate (Suclear, Braintree Laboratories, Braintree, MA) were all approved in the United States in the last several years. In addition to these prescriptive agents, several over-the counter (OTC) products are used, the most common of which are PEG-3350 powder, magnesium citrate, and bisacodyl tablets.


Bowel preparation formulations are assessed based on 3 criteria: efficacy, safety, and tolerability. We assume that important differences in safety among the most widely used prescriptive agents, which would influence our prescribing pattern, do not exist. The choice among agents therefore rests on their relative efficacy, tolerability, and in some instances cost. The comparative efficacy of bowel cleansing regimens before colonoscopy has been assessed and quantified in countless clinical trials, systematic reviews, and meta-analyses. Differences in dosing regimens, dietary restrictions, patient populations, use of adjunctive agents, and methods for assessing outcomes among studies have sometimes led to conflicting results. A 2014 US MSTF guideline concluded that split-dose 4-L PEG with electrolytes provides high-quality bowel cleansing. The guideline also indicates that a lower-volume PEG formulation (2 L) achieves bowel cleansing in healthy nonconstipated individuals that is not inferior to that of a 4-L formulation. This conclusion was supported by a recent meta-analysis of 11 trials, representing 3443 patients, which compared 2-L PEG plus ascorbate with 4-L PEG. The pooled OR for preparation efficacy was 1.08 (95% CI, 0.98–1.28; P = .34). Tolerability was superior with 2-L PEG with ascorbate compared with 4-L PEG (OR, 2.23; 95% CI, 1.67–2.98; P <.00001).


The efficacy and tolerability of oral sodium sulfate (OSS) have been evaluated in at least 4 unique multicenter trials against a variety of other agents. In a study of 923 patients, representing the combined results of 2 parallel studies, OSS was not inferior to 2-L PEG with ascorbate (OR, 1.12, 0.77–1.62). Another study of OSS compared sodium sulfate in a split-dose with 4-L PEG taken the day before. The superiority of OSS (98.4% vs 89.6%; P <.04) reflected both the efficacy of the agent and the benefits of split dosing. A multicenter trial of 338 randomized patients resulted in a higher proportion of successful preparations (excellent or good) with OSS compared with sodium picosulfate plus magnesium citrate (94.7% vs 85.7%; P = .006) when both preparations were given in split doses. Another multicenter trial compared a new hybrid preparation, consisting of a reduced dose of OSS plus 2 L of sulfate-free (SF) PEG with electrolytes versus 2 different 2-L PEG preparations. Study 1, which compared split-dose OSS plus SF-PEG with 2-L PEG with ascorbate, found identical rates of excellent or good bowel preparation (93.5%) in both arms. Study 2, which compared OSS plus SF-PEG versus 2-L PEG plus 10 mg of bisacodyl, both taken the evening before colonoscopy, resulted in successful preparation in 89.8% and 83.5%, respectively. With respect to patient tolerability, vomiting was more frequent with OSS plus SF-PEG, whereas bloating was worse with PEG with ascorbate.


Sodium picosulfate combined with magnesium salts was approved by the US Food and Drug Administration for bowel cleansing before colonoscopy in 2012, after achieving considerable acceptance in Canada, Europe, and Australia. An analysis of 10 trials comparing sodium picosulfate combined with either magnesium oxide or magnesium citrate showed no significant difference in efficacy compared with PEG with electrolytes (OR, 0.92, 0.63–1.36). One trial of 250 intention-to-treat patients compared picosulfate split-dose versus picosulfate taken either the day before or the same day. The split-dosing regimen had a significantly higher proportion of adequate preparations compared with day before or same day (OR, 3.54, 1.95–6.45). A large multicenter trial of 862 patients, which randomized 2:1 split-dose versus day-before dosing of picosulfate plus magnesium citrate, observed 85.8% adequate preparation with split dosing compared with 69.8% in the group receiving the preparation the day before colonoscopy.


Issues regarding the safety of oral sodium phosphate preparations have been raised in recent years, because of concerns about the risk of major fluid and electrolyte shifts as well as chronic kidney disease resulting from acute phosphate nephropathy. Risk factors that predispose patients to acute phosphate nephropathy include renal insufficiency (as reflected in a reduced creatinine clearance rate), inadequate hydration during bowel preparation, reduced time interval between the 2 doses of sodium phosphate (less than 12 hours), hypertension with renal arteriolar sclerosis, and certain medications (diuretics, nonsteroidal antiinflammatory drugs, and renin-angiotensin inhibitors). In addition, heart failure, cirrhosis, and advanced age may also be risk factors for acute phosphate nephropathy. The risks associated with the use of sodium phosphate are now thought to make its use as a first-line agent for precolonoscopy bowel preparation unsuitable. Appropriate cautions, as indicated in the product label, should be exercised when using this agent for bowel preparation before colonoscopy.


Over-the-counter Agents


Several OTC laxative agents have been adapted for use during bowel cleansing before colonoscopy. In the United States, the 2 most widely used compounds are PEG-3350 powder and magnesium citrate. Although these products are generally safe when used for their intended purpose, their safety as well as their efficacy for preprocedure bowel cleansing is largely unknown.


The most frequently used formula for PEG powder consists of 1 bottle of PEG-3350 (238 g) mixed with 1890 mL (64 ounces) of Gatorade (PepsiCo, Chicago, IL) to create a 2-L PEG preparation. Bisacodyl tablets or magnesium citrate are sometimes given in combination with the PEG solution. A meta-analysis of 5 studies, comprising 1418 patients, assessed the efficacy and tolerability of PEG powder with Gatorade compared with standard PEG with electrolytes (3.8–4 L). PEG-3350 powder was associated with fewer satisfactory bowel preparations compared with larger-volume PEG plus electrolytes (OR, 0.65; 95% CI, 0.43–0.98; P = .04). However, no difference in polyp detection was observed between treatment groups. Patient willingness to repeat their preparation was superior with PEG powder compared with larger-volume PEG (OR, 7.32; 95% CI, 4.88–10.98; P <.01).


The use of magnesium citrate, an OTC laxative packaged in a 300-mL (10-ounce) bottle, has achieved significant market share in the United States, according to anecdotal reports. When used at a dose of 300 mL times 3, it produced excellent or good-quality bowel cleansing in 94% and 97% of cases in the right and left colon, respectively. Transient hypermagnesemia has been reported, although clinically important adverse events have not been observed in healthy persons. The use of magnesium-based agents should be avoided in patients with chronic kidney disease.


Adjunctive Agents


A variety of adjunctive agents designed to improve evacuation, mucosal cleansing, and/or patient tolerability have been assessed. The list of such compounds, although not exhaustive, includes senna, bisacodyl, menthol, olive oil, promotility agents, sodium ascorbate, sodium sulfate, probiotics, spasmolytics, and simethicone. However, no adjunctive agent has been established to consistently improve the efficacy of colonoscopy or the tolerability for bowel preparation. This conclusion is supported by both the US and European guidelines. Nevertheless, clinicians sometimes find benefit in the use an adjunctive agent. For example, the use of simethicone to eliminate bubbles or foam seems sensible despite the absence of scientific evidence supporting its utility. A thorough review of this subject is beyond the scope of this article and interested readers are referred to a recent review article on the subject.


Strategies for Hard-to-prepare Patients


Individuals with 1 or more risk factors for an inadequate bowel preparation, in particular those with a history of chronic constipation, multiple comorbid conditions, or an inadequate bowel preparation previously, need a more intensive bowel cleansing regimen. In such cases, a 4-L PEG preparation with electrolytes seems to be preferable to a 2-L PEG preparation. Although there are no published studies to support this statement, it seems to be intuitive and is supported by expert opinion. Another approach is the addition of an adjunctive agent such as 300 mL (10 ounces) of magnesium citrate or 10 mg of bisacodyl to a standard 2-L or 4-L PEG. Again, there is only anecdote to support these approaches because published data on bowel preparation in these patient subgroups are absent.


However, what is known is that a sizable proportion of patients (23%) with an inadequate preparation at their first examination will have an inadequate preparation on repeat examination. An exception to this is next-day (salvage) colonoscopy, for which the odds of repeat failure are significantly reduced (OR, 0.31; 95% CI, 0.1–0.92). In another study of patients with an inadequate preparation after 4-L PEG, 20-mg oral bisacodyl combined with 4-L PEG was associated with a salvage rate of 80% on repeat procedure. Even more successful was an intensive regimen that included a low-residue diet for 72 hours followed by liquids for 24 hours, combined with 10 mg of oral bisacodyl plus 1.5 L of PEG with electrolytes the evening before procedure, and another 1.5-L PEG with electrolytes on the day of colonoscopy. Ninety percent of patients had an adequate preparation as assessed using the Boston Bowel Preparation Scale (BBPS).

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Sep 10, 2017 | Posted by in GASTOINESTINAL SURGERY | Comments Off on Advances in Bowel Preparation for Colonoscopy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access